Post-viral alterations in periodontal health in individuals recovering from COVID-19.

Post-viral alterations in periodontal health in individuals recovering from COVID-19.

Publication date: Jun 25, 2025

This study explores post-viral immune modulation in periodontal health using COVID-19 convalescence as a model. We hypothesized that post-COVID-19 recovery induces epigenetic alterations, measurable through salivary methyl-transferase-like 3 (METTL3) expression and clinical-periodontal parameters. The present research comprises results from two studies: the clinical study, which included a total of 83 systemically healthy adults stratified into four groups according to periodontal status and COVID-19 history, and the laboratory study on human parotid gland samples (n = 10). Full-mouth periodontal status and unstimulated morning saliva were obtained. Glandular METTL3 and fat mass and obesity-associated factor as well as salivary METTL3 and cortisol were quantified using ELISA; psychological stress was assessed with the Perceived Stress Scale -10. Effect sizes were assessed using ANOVA and multivariable linear regression, and receiver operating characteristic (ROC) curves were generated for METTL3. Decreased levels of METTL3 in parotid tissue and in saliva of COVID-19 convalescents were found. Prior COVID-19 was significantly associated with METTL3 and plaque index (PI) as predictors, when adjusted for age, gender, periodontitis, and salivary cortisol. Strong associations between METTL3 and PI were found. Stress scores and cortisol did not differ between groups. Thus, downregulation of salivary METTL3 and concomitant plaque index reduction characterize the late convalescent phase of COVID-19. These epigenetic changes may reflect post-viral changes in parotid gland and periodontal health homeostasis and warrant longitudinal research confirmation.

Open Access PDF

Concepts Keywords
Homeostasis epigenetics
Morning methyl-transferase-like 3
Obesity periodontitis
Salivary post-COVID-19
Viral saliva

Semantics

Type Source Name
disease MESH COVID-19
disease MESH convalescence
disease IDO history
disease MESH obesity
drug DRUGBANK Hydrocortisone
disease MESH psychological stress
drug DRUGBANK Saquinavir
disease MESH periodontitis
pathway REACTOME Reproduction
disease IDO host
disease IDO virulence
disease MESH viral infection
disease MESH infection
disease MESH dysbiosis
disease MESH inflammation
pathway REACTOME Methylation
disease IDO assay
drug DRUGBANK Methionine
disease MESH tumor
disease IDO symptom
disease MESH pneumonia
disease MESH dyspnea
disease MESH hypoxia

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *